The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease

James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll

doi:10.1111/bph.13576

journal article Sep 23, 2016

The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease

James C Evans Meenakshi Malhotra John F Cryan Caitriona M O'Driscoll

British Journal of Pharmacology Vol. 173 No. 21 pp. 3041-3079 · Wiley

View at Publisher Save 10.1111/bph.13576

Abstract

Prostate specific membrane antigen (PSMA) otherwise known as glutamate carboxypeptidase II (GCPII) is a membrane bound protein that is highly expressed in prostate cancer and in the neovasculature of a wide variety of tumours including glioblastomas, breast and bladder cancers. This protein is also involved in a variety of neurological diseases including schizophrenia and ALS. In recent years, there has been a surge in the development of both diagnostics and therapeutics that take advantage of the expression and activity of PSMA/GCPII. These include gene therapy, immunotherapy, chemotherapy and radiotherapy. In this review, we discuss the biological roles that PSMA/GCPII plays, both in normal and diseased tissues, and the current therapies exploiting its activity that are at the preclinical stage. We conclude by giving an expert opinion on the future direction of PSMA/GCPII based therapies and diagnostics and hurdles that need to be overcome to make them effective and viable.

Topics

No keywords indexed for this article. Browse by subject →

References

272

[1]

10.1016/j.prp.2014.05.015

[2]

10.1002/cmmi.1514

[3]

10.1007/s00259-014-2949-6

[4]

10.1007/s00259-013-2525-5

[5]

10.1186/s13550-015-0114-2

[6]

10.1155/2012/973820

[7]

10.1111/bph.13354

[8]

10.1111/bph.13353

[9]

10.1111/bph.13347

[10]

10.1111/bph.13355

[11]

10.1111/bph.13352

[12]

10.1016/j.mvr.2006.03.004

[13]

Anilkumar G "Prostate‐specific membrane antigen association with filamin A modulates its internalization and NAALADase activity" Cancer Res (2003)

[14]

10.1093/annonc/mdv209

[15]

10.1002/pros.22850

[16]

10.1016/j.jconrel.2014.10.018

[17]

10.1021/nl071546n

[18]

10.1593/neo.13986

[19]

10.1016/j.nucmedbio.2014.01.001

[20]

10.2967/jnumed.113.125476

[21]

10.1200/jco.2005.05.160

[22]

10.2967/jnumed.114.149062

[23]

10.1021/jm401921j

[24]

10.2174/092986712799034888

[25]

10.1110/ps.04622104

[26]

10.2967/jnumed.112.111203

[27]

10.7150/ijms.3635

[28]

10.1074/jbc.m110.111765

[29]

Behe M "In vivo testing of 177Lu‐labelled anti‐PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer" In Vivo (2011)

[30]

10.1039/c4nr06069e

[31]

10.1111/j.1471-4159.2003.02321.x

[32]

Bouchelouche K "Prostate specific membrane antigen—a target for imaging and therapy with radionuclides" Discov Med (2010)

[33]

Bruno V "Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor‐β" J Neurosci (1998) 10.1523/jneurosci.18-23-09594.1998

[34]

10.1186/s12868-016-0251-1

[35]

10.1007/s00259-015-3078-6

[36]

Chang SS "Prostate‐specific membrane antigen is produced in tumor‐associated neovasculature" Clin Cancer Res (1999)

[37]

Chang SS "Five different anti‐prostate‐specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor‐associated neovasculature" Cancer Res (1999)

[38]

10.1007/978-1-59259-776-5_34

[39]

10.1016/s0090-4295(99)00600-7

[40]

10.2967/jnumed.115.156729

[41]

10.1002/pros.22941

[42]

10.1124/jpet.300.2.662

[43]

10.1158/1078-0432.ccr-11-1357

[44]

10.1002/mc.21850

[45]

10.1021/nn301725w

[46]

10.2967/jnumed.112.104661

[47]

Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes

Ji-Young Choi, Jong-Ho Kim, Sangmee Ahn Jo

Biochemical and Biophysical Research Communication... 10.1016/j.bbrc.2014.05.132

[48]

10.1016/j.bios.2005.12.015

[49]

10.1007/s10456-013-9360-y

[50]

10.1128/mcb.00084-06

Showing 50 of 272 references

Metrics

104

Citations

272

References

Details

Published: Sep 23, 2016
Vol/Issue: 173(21)
Pages: 3041-3079
License: View

Authors

J

James C Evans

Pharmacodelivery Group, School of Pharmacy University College Cork Cork Ireland

M

Meenakshi Malhotra

Pharmacodelivery Group, School of Pharmacy University College Cork Cork Ireland

J

John F Cryan

Department of Anatomy and Neuroscience University College Cork Cork Ireland

C

Caitriona M O'Driscoll

Pharmacodelivery Group, School of Pharmacy University College Cork Cork Ireland

Funding

Irish Research Council Award: GOIPD/2014/151

Council for the Development of Social Science Research in Africa Award: PCI11ODR

Cite This Article

James C Evans, Meenakshi Malhotra, John F Cryan, et al. (2016). The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. British Journal of Pharmacology, 173(21), 3041-3079. https://doi.org/10.1111/bph.13576

The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease

You May Also Like